Jan 15, 2026 07:07AM
Dec 15, 2025 07:31AM
Dec 11, 2025 07:32AM
Nov 12, 2025 02:22PM
Nov 12, 2025 08:03AM
Oct 30, 2025 10:45AM
Oct 13, 2025 07:30AM Abeona gene therapy selected for FDA rare disease pilot program
Oct 13, 2025 06:49AM
Oct 8, 2025 07:31AM
Aug 14, 2025 04:24PM
Jul 14, 2025 07:00AM
Jul 14, 2025 06:59AM
Jul 2, 2025 07:33AM
Jul 1, 2025 07:30AM Abeona Therapeutics (ABEO) Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
Jun 25, 2025 02:24PM
Jun 2, 2025 08:48AM
May 16, 2025 09:34AM
May 15, 2025 07:36AM
May 12, 2025 07:30AM
Apr 29, 2025 01:22PM
Apr 29, 2025 06:57AM Abeona Therapeutics (ABEO): U.S. FDA Approves ZEVASKYN, the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa
Apr 8, 2025 05:28AM
Mar 20, 2025 01:41PM
Mar 5, 2025 06:53AM
Nov 27, 2024 07:00AM
Nov 27, 2024 07:00AM
Nov 25, 2024 06:47AM
Nov 12, 2024 07:31AM Abeona Therapeutics (ABEO) Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
Oct 29, 2024 07:32AM
Aug 14, 2024 07:31AM
Aug 13, 2024 07:30AM
Aug 12, 2024 07:39AM
Aug 12, 2024 07:31AM
Jul 12, 2024 08:16AM
Jul 11, 2024 07:30AM Abeona Therapeutics (ABEO) and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204
Jun 12, 2024 07:29AM

341,965 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All